Amazentis’s new cellular nutrient Urolithin A promises to improve cellular health and reverse aging effects in muscles. The food giant Nestlé has bought an equity stake in the startup to receive global rights to develop products such as supplements and beverages based on Amazentis' technology.
The Lausanne based startup, Amazentis, is a pioneer in science-driven nutritional health. The startup’s flagship product, Urolithin A is the first natural bioactive dietary metabolite that is naturally produced when eating certain foods, such as the pomegranate, which are believed to clean up damage in cellular powerhouses called mitochondria. Optimal mitochondrial function is central to cell metabolism and overall health. This is part of a new class of nutrients, called cellular nutrients, which go beyond traditional macro and micronutrients and are clinically proven to improve cellular health.
The global food giant Nestlé Health Science now seeks to leverage this technology as part of its growth strategy in consumer healthcare and medical nutrition. NSH has entered a global partnership with Amazentis through the purchase of equity stake in Amazentis. NHS will receive global rights to use Amazentis’ patented Urolithin A technology for dietary supplements, select foods and beverages, and medical nutrition products.
Amazentis retains co-exclusive rights for the online distribution of dietary supplements and select food products as well as global exclusive rights for distribution of certain other defined categories. Nestlé Health Science and Amazentis will also conduct a joint research program to expand applications of Urolithin A into new consumer health and medical benefit areas.
“Advancing cellular nutrition is a key component of our strategy to bring new benefits to consumers and patients. Amazentis’ impressive science in the field of mitochondrial health opens significant new opportunities for us, and we are thrilled to partner with their capable team. Our global strategic partnership will include a significant investment to support further research and development of Urolithin A”, Greg Behar, CEO of Nestlé Health Science.
“We're excited to be partnering with Nestlé Health Science as they truly see the future of nutrition and share our vision of developing a new generation of clinically validated nutrients to counteract cellular aging. Urolithin A is the only clinically tested natural bioactive shown to improve mitochondrial health by activating the selective recycling of damaged mitochondria. This partnership will enable us to make this breakthrough more widely available and will support consumers in the proactive management of their cellular health", says Chris Rinsch, Co-founder and CEO Amazentis.
(Press release/ran)
Please login or sign up to comment.
Commenting guidelines